GNAL

Across TCGA pan-cancer cohorts, GNAL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GNAL data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher GNAL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNAL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, HNSC, and LIHC are the cancer types where GNAL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	III,IV	0.081	0.738	<.001	9	view →
HNSC	DFS	Median	All	0.098	0.710	<.001	7	view →
LIHC	OS	Median	III,IV	0.195	0.648	.013	6	view →
UCEC	DFS	Median	All	0.903	0.619	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GNAL–THCA (DFS)

Open the THCA breakdown →